Chronic granulomatous disease (CGD) is a rare inherited immune deficiency caused due to a random mutation in the DNA. People affected with this disease have weakened immune systems which do not function properly. CGD is of two types, namely, X-linked CGD and autosomal recessive type.
According to The Chronic Granulomatous Disorder Society, about 60% of people with CGD have X-linked CGD. People with CGD generally have bacterial infections including Salmonella, Klebsiella, Actinomyces, Streptococcus, Nocardia, and Serratia among others. Moreover, fungal infections such as Aspergillus fumigatus and Aspergillus nidulans are also common.
Factors such as the growing prevalence of rare diseases, increasing expenditure on healthcare sector in the developed economies, and increasing research and development activities are anticipated to drive the growth of the market.
However, expensive diagnostic tests and lack of awareness about the disease in the developing and underdeveloped economies may hinder the market growth over the forecast period. For instance, the cost of genetic testing ranges from USD 100 to USD 2,000.
Avail Sample Copy for This Report at: https://www.marketresearchfuture.com/sample_request/6447
Some of the prominent players in the global chronic granulomatous disease market are Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc.
Global Chronic Granulomatous Disease Market, by Type
X-Linked Chronic Granulomatous Disease
Autosomal Recessive Chronic Granulomatous Disease
Global Chronic Granulomatous Disease Market, by Diagnosis
Neutrophil Function Tests
Global Chronic Granulomatous Disease Market, by Treatment
Stem cell transplantation
Global Chronic Granulomatous Disease Market, by End-User
Geographically, Americas is expected to dominate the global chronic granulomatous disease market during the forecast period owing to the growing prevalence of rare diseases, increasing research and development, and presence of well-developed healthcare sector. Europe is anticipated to hold the second largest position in the global chronic granulomatous disease market.
Brows Detailed Report and Avail Discount Enquiry at: https://www.marketresearchfuture.com/reports/chronic-granulomatous-disease-market-6447
The market growth in this region is attributed to the rising prevalence of rare diseases and increasing research and development activities. Asia-Pacific is expected to be the fastest growing market owing to the developing healthcare infrastructure, increasing awareness about rare genetic diseases, and increasing government funding for the healthcare sector.
Furthermore, the Middle East and Africa region is expected to hold the least share in the global market owing to the slowly developing healthcare sector especially in the African region.
About Market Research Future:
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
+1 646 845 9312